TGA Updates Import Rules for Peptide Research Compounds

The Australian Therapeutic Goods Administration has updated its guidance on the Personal Importation Scheme as it applies to peptide research compounds. The revised guidance specifically addresses the importation of synthetic peptides including TB-500 (Thymosin Beta-4 fragment) and BPC-157, clarifying that these substances require a valid prescription from an Australian registered medical practitioner for legal importation under the scheme.

The Personal Importation Scheme allows individuals to import medicines that are not available in Australia, provided certain conditions are met. These conditions include a maximum three-month supply, personal use only, and — critically — a prescription from an Australian prescriber for prescription-only or controlled substances. The TGA's updated guidance makes clear that synthetic peptides marketed for research purposes fall within the scope of these requirements when imported for human use.

This clarification is significant for Australian consumers who have previously imported research peptides through international suppliers without prescriptions. While enforcement of the Personal Importation Scheme at the border has historically been inconsistent, the updated guidance provides Australian Border Force with a clearer framework for intercepting non-compliant shipments.

The TGA notes that consumers who import unapproved peptide products do so at their own risk, as these products have not been evaluated by the agency for quality, safety, or efficacy. Healthcare professionals in Australia who prescribe unapproved peptides under the Authorised Prescriber or Special Access Scheme pathways are reminded of their reporting obligations.